About INVIRSA, INC.
Invirsa is a biotechnology company developing treatments for ocular conditions associated with DNA damage, including sulfur mustard gas injury and diabetic dry eye. The company has partnered with BARDA and secured significant funding for the development of its lead compound, INV-102.
Development of novel therapeutics targeting DNA damage responseClinical trial execution and regulatory submissionsPharmaceutical development and program management
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. | Department of Health and Human Services | $39.0M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to INVIRSA, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.